Department of Obstetrics and Gynecology, School of Medicine, University of Ondokuz Mayis, Samsun, Turkey.
Eur J Obstet Gynecol Reprod Biol. 2010 May;150(1):84-7. doi: 10.1016/j.ejogrb.2010.02.004. Epub 2010 Feb 25.
To compare the efficacies of anastrozole and raloxifene on endometriosis.
A randomized, placebo-controlled, single-blind, experimental study was performed on 45 adult Wistar female rats in the Experimental Surgery Laboratory at Ondokuz Mayis University in Turkey. Endometrial tissues were implanted on the abdominal peritoneum in 45 rats. Six weeks later, the implant volumes were measured (volume-1) by performing a second laparotomy. Rats were randomized to one of three equal study groups. Saline solution (0.1 cc/rat/week, subcutaneously) was administered to group 1 (control group), anastrozole (0.004 mg/rat/day, orally) to group 2 (anastrozole group), and raloxifene (0.24 mg/rat/day, orally) to group 3 (raloxifene group) for 8 weeks. At the end of administration, a third laparotomy was performed to remeasure implant volumes (volume-2), and implants were totally excised for histopathologic examination. Volume-1 and volume-2 within the groups, as well as stromal and glandular tissues between the groups, were compared.
RESULT(S): In the anastrozole and raloxifene groups, volume-2 values were significantly lower than those of volume-1. When compared to the control group, in both anastrozole and raloxifene groups, while glandular tissue scores were found significantly lower, stromal tissue scores were not different than that of the control group. There was no significant difference between both the GT and ST scores of the anastrozole and raloxifene groups.
CONCLUSION(S): Anastrozole and raloxifene were seen to have caused equally the regression of the experimental endometriosis statistically significantly.
比较阿那曲唑和雷洛昔芬治疗子宫内膜异位症的疗效。
在土耳其奥登尼兹·马伊斯大学实验外科实验室，对 45 只成年 Wistar 雌性大鼠进行了一项随机、安慰剂对照、单盲、实验研究。将子宫内膜组织植入 45 只大鼠的腹部腹膜中。6 周后，通过再次剖腹术测量植入物体积（体积-1）。将大鼠随机分为三组，每组 15 只。第 1 组（对照组）给予生理盐水（0.1 cc/大鼠/周，皮下注射），第 2 组（阿那曲唑组）给予阿那曲唑（0.004 mg/大鼠/天，口服），第 3 组（雷洛昔芬组）给予雷洛昔芬（0.24 mg/大鼠/天，口服），治疗 8 周。给药结束时，进行第三次剖腹术以重新测量植入物体积（体积-2），并完全切除植入物进行组织病理学检查。比较组内的体积-1 和体积-2，以及组间的基质和腺体组织。
在阿那曲唑和雷洛昔芬组中，体积-2 值明显低于体积-1 值。与对照组相比，阿那曲唑和雷洛昔芬组的腺体组织评分明显降低，而基质组织评分与对照组无差异。阿那曲唑和雷洛昔芬组的 GT 和 ST 评分无显著差异。
阿那曲唑和雷洛昔芬同样显著地导致实验性子宫内膜异位症的消退。
